Why Geron Corporation Stock Is Jumping Today
Shares of the clinical-stage biotech Geron Corporation (NASDAQ: GERN) rose by as much as 13.5% in early morning trading today, thanks to a Fast Track designation from the U.S. Food and Drug Administration (FDA) for the company's experimental blood-cancer medicine, imetelstat, as a treatment for adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes.
Imetelstat is a first-in-class telomerase inhibitor being developed by Johnson & Johnson's (NYSE: JNJ) biotech subsidiary Janssen through an exclusive worldwide licensing deal with Geron.
Image source: Getty Images.
Source: Fool.com
Johnson & Johnson Stock
€135.12
-0.220%
With 42 Buy predictions and 1 Sell predictions Johnson & Johnson is one of the favorites of our community.
As a result the target price of 179 € shows a positive potential of 32.47% compared to the current price of 135.12 € for Johnson & Johnson.
